文献速递肿瘤 PET/CT

表皮生长因子受体状态与乳腺癌FDG摄取强相关

Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-05-09

本研究回顾性纳入499例初诊原发性乳腺癌患者,于治疗前PET/CT测量肿瘤SUVmax,并以免疫组化评估生物标志物。EGFR表达与更高的SUVmax相关,且是多因素分析中高FDG摄取的独立预测因子,其影响超出激素受体和HER2状态。

要点

  • EGFR阳性肿瘤SUVmax为11.9±6.0,高于EGFR阴性肿瘤的8.3±5.3。
  • EGFR阳性肿瘤中73.2%为高FDG摄取,EGFR阴性肿瘤中为40.6%。
  • 多因素分析中EGFR阳性是高FDG摄取的独立预测因子。

核心结论

  • 原发性乳腺肿瘤FDG摄取受EGFR状态强烈影响,且该影响超出激素受体和HER2等其他主要生物标志物的作用。
  • EGFR表达是高乳腺肿瘤FDG摄取的强独立预测因子。

研究设计与样本

  • 回顾性研究,纳入499例初诊原发性乳腺癌患者。
  • 于治疗前PET/CT测量肿瘤FDG摄取,以最大标准化摄取值(SUVmax)表示。
  • 生物标志物通过肿瘤组织免疫组化评估。
  • 对高肿瘤FDG摄取(SUVmax≥8.6)的预测因素进行回归分析。

主要发现

  • ER阴性肿瘤SUVmax为11.2±6.0,高于ER阳性肿瘤的8.3±5.3(p<0.0001)。
  • PR阴性肿瘤SUVmax为10.9±6.0,高于PR阳性肿瘤的8.2±5.2(p<0.0001)。
  • 三阴性肿瘤SUVmax为12.0±6.9,高于非三阴性肿瘤的8.7±5.2(p<0.0001)。
  • EGFR表达见于28.5%的肿瘤,在ER阴性、PR阴性、三阴性、细胞角蛋白5/6(CK5/6)阳性和突变型P53(mP53)阳性肿瘤中更常见(均p<0.0001)。
  • EGFR阳性肿瘤高FDG摄取占73.2%,EGFR阴性肿瘤占40.6%。

关键数值与推荐

  • 高肿瘤FDG摄取定义为SUVmax≥8.6。
  • 全部受试者的多因素分析中,高FDG摄取的显著预测因素为大体积、EGFR阳性和CK5/6阳性。
  • ER阴性和激素受体阴性亚组的多因素分析中,高FDG摄取的显著预测因素为EGFR阳性和CK5/6阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Imaging tumor FDG uptake could complement breast cancer biomarkers of risk and treatment response. Although breast cancer FDG uptake is reputedly influenced by major biomarker states, the role of epidermal growth factor receptor (EGFR) expression remains largely unexplored. METHODS: This is a retrospective study that included 499 patients with primary breast cancer at initial presentation. Tumor FDG uptake was measured on pretreatment PET/CT as maximum standardized uptake value (SUVmax), and biomarkers were assessed by immunohistochemistry of tumor tissue. Regression analysis was performed for predictors of high tumor FDG uptake (SUVmax ≥ 8.6). RESULTS: SUVmax was higher in ER- (36.5%; 11.2 ± 6.0 vs. 8.3 ± 5.3), PR- (42.3%; 10.9 ± 6.0 vs. 8.2 ± 5.2), and triple-negative tumors (19.8%; 12.0 ± 6.9 vs. 8.7 ± 5.2; all p < 0.0001). EGFR expression (28.5%) was more frequent in ER-, PR-, triple-negative, cytokeratin 5/6 (CK5/6) + and mutant P53 (mP53) + tumors (all p < 0.0001). EGFR+ was associated with higher SUVmax among all tumors (11.9 ± 6.0 vs. 8.3 ± 5.3), ER- tumors (p < 0.0001), PR- and + tumors (p < 0.0001 and 0.027), hormone receptor- and + tumors (p < 0.0001 and 0.004), human epidermal growth factor receptor 2 (HER2)- and + tumors (p < 0.0001 and 0.006), non-triple negative tumors (p < 0.0001), CK5/6- and + tumors (p = 0.021 and <0.0001), and mP53- and + tumors (p < 0.0001 and 0.008). Tumors had high FDG uptake in 73.2% of EGFR+ and 40.6% of EGFR- tumors. On regression analysis, significant multivariate predictors of high tumor FDG uptake were large size, EGFR+ and CK5/6+ for the entire subjects, and EGFR+ and CK5/6+ for ER- and hormone receptor negative subgroups. High FDG uptake was able to sub-stratify EGFR+ tumors that were more likely to be ER- and CK5/6+, and EGFR- tumors more likely to be mP53 +. CONCLUSIONS: Primary breast tumor FDG uptake is strongly influenced by EGFR status beyond that by other major biomarkers including hormone receptor and HER2 status, and EGFR expression is a strong independent predictor of high breast tumor FDG uptake.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee J, Lee EJ, Moon SH, et al. Strong association of epidermal growth factor receptor status with breast cancer FDG uptake. Eur J Nucl Med Mol Imaging. 2017. PMID: 28488029. doi:10.1007/s00259-017-3705-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。